In February, Novo Holdings announced one of the largest M&A deals in recent memory with its plans to acquire Catalent, a leading contract drug manufacturer, for a cool $16.5 billion. The deal could accelerate production of Novo Nordisk’s blockbuster diabetes and weight-loss medications, Ozempic and Wegovy, given skyrocketing demand. But while the Novo-Catalent deal marks…
Biotech bloodbath? Nearly 100 companies announce layoffs in the first half of 2023, but job openings also surge
The first half of 2023 brought job cuts to roughly 100 biotech and pharma companies. But while that may indicate an unstable employment landscape, it is not a universal trend. Since March, appetite for life sciences talent has gathered steam. According to data from real-estate firm JLL, June 2023 had the sixth highest number of…